Author: admin

“Severe Hypertriglyceridemia Pipeline Insights”

DelveInsight’s “Severe Hypertriglyceridemia – Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Severe Hypertriglyceridemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Major players such as Arrowhead Pharmaceuticals, Ionis Pharmaceuticals, 89bio, Regeneron Pharmaceuticals, Kowa Research Institute, Mochida Pharmaceutical, Acasti Pharma, NorthSea Therapeutics, Matinas BioPharma, and others are developing various therapies for the SHTG which will drive the severe hypertriglyceridemia market in the upcoming years. 

The expected launch of emerging therapies such as Evinacumab, ARO-APOC3, and others are anticipated to improve the Severe Hypertriglyceridemia treatment scenario in the coming years.

The Severe Hypertriglyceridemia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from pre-clinical developmental to marketed phases. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Severe Hypertriglyceridemia Overview

Severe hypertriglyceridemia is a condition characterized by extremely high levels of triglycerides in the blood, typically defined as levels above 500 mg/dL (5.6 mmol/L). Triglycerides are a type of fat (lipid) found in the blood, and having elevated levels increases the risk of cardiovascular disease and can lead to pancreatitis, a potentially life-threatening inflammation of the pancreas.

Causes

– Genetic Factors: Conditions such as familial hypertriglyceridemia, familial combined hyperlipidemia, and familial chylomicronemia syndrome.

– Lifestyle Factors: High-fat diets, excessive alcohol consumption, obesity, and physical inactivity.

– Medical Conditions: Diabetes (especially poorly controlled), hypothyroidism, kidney disease, and metabolic syndrome.

– Medications: Some drugs, such as beta-blockers, diuretics, oral estrogen, and corticosteroids, can elevate triglyceride levels.

Symptoms

Severe hypertriglyceridemia itself often does not cause symptoms until it leads to complications such as pancreatitis. Symptoms of pancreatitis can include:

– Severe abdominal pain that may radiate to the back

– Nausea and vomiting

– Fever

– Rapid heartbeat

Diagnosis

– Blood Tests: Triglyceride levels are measured through blood tests, often as part of a lipid panel that also includes cholesterol levels.

– Genetic Testing: May be considered if a hereditary condition is suspected.

– Medical History and Physical Examination: Assess for risk factors and signs of related conditions.

Complications

– Pancreatitis: Inflammation of the pancreas, which can be acute or chronic.

– Cardiovascular Disease: Increased risk of coronary artery disease, heart attack, and stroke.

– Fatty Liver Disease: Accumulation of fat in the liver can lead to nonalcoholic fatty liver disease (NAFLD).

Treatment

– Lifestyle Modifications:

  – Dietary Changes: Adopting a low-fat, low-sugar diet rich in fruits, vegetables, whole grains, and lean proteins. Reducing or eliminating alcohol intake.

  – Weight Management: Achieving and maintaining a healthy weight through diet and exercise.

  – Physical Activity: Regular exercise to help lower triglyceride levels and improve overall health.

– Medications:

  – Fibrates: Drugs like fenofibrate and gemfibrozil can lower triglyceride levels.

  – Omega-3 Fatty Acids: Prescription fish oil supplements can be effective.

  – Statins: Primarily used to lower cholesterol but can also reduce triglycerides.

  – Niacin: Can lower triglycerides but may have side effects.

– Management of Underlying Conditions: Controlling diabetes, hypothyroidism, and other related conditions can help manage triglyceride levels.

– Avoiding Triglyceride-Elevating Medications: When possible, switch to alternative medications that do not raise triglyceride levels.

Monitoring and Follow-Up

Regular monitoring of triglyceride levels and overall lipid profile is essential to assess the effectiveness of treatment and make necessary adjustments. Ongoing communication with healthcare providers is crucial for managing severe hypertriglyceridemia and preventing complications.

Severe Hypertriglyceridemia Pipeline Analysis

The report provides insights into: 

• The report provides detailed insights into the emerging therapies for the treatment of Severe Hypertriglyceridemia and the aggregate therapies developed by major pharma companies.

• It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

• It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

• It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Severe Hypertriglyceridemia market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Analysis of Emerging Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

• Late stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) 

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

Route of Administration

Severe Hypertriglyceridemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Inhalation

• Inhalation/Intravenous/Oral

• Intranasal

• Intravenous

• Intravenous/ Subcutaneous

• Oral

• Oral/intranasal/subcutaneous

• Parenteral

• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types, such as

• Antibody

• Antisense oligonucleotides

• Immunotherapy

• Monoclonal antibody

• Peptides

• Protein

• Recombinant protein

• Small molecule

• Stem Cell

• Vaccine

Severe Hypertriglyceridemia Therapeutics Landscape

Current treatments typically provide modest reductions in triglycerides, leaving many people uncontrolled and at risk of developing pancreatitis. Therefore, there is a significant need for new therapies that can substantially lower triglyceride levels in the bloodstream to further minimize the impact of this serious condition.

To improve the treatment scenario, about 10+ key companies are developing therapies for Severe Hypertriglyceridemia. Currently,  Ionis Pharmaceuticals is leading the therapeutics market with its Severe Hypertriglyceridemia drug candidates in the most advanced stage of clinical development.

Leading Companies in the Severe Hypertriglyceridemia (SHTG) Therapeutics Market Include:

• 89bio, Inc

• Acasti Pharma Inc.

• Amarin Corporation

• Arrowhead

• Ionis Pharmaceuticals

• Kowa Research Institute, Inc.

• Matinas BioPharma

• Mochida Pharmaceutical

• NorthSea Therapeutics B.V.

• Pfizer

• Regeneron

Severe Hypertriglyceridemia Emerging and Marketed Drugs Profile:

• ARO-APOC3: Arrowhead

• Evinacumab: Regeneron

• Olezarsen: Ionis Pharmaceuticals

• SEFA-1024: NorthSea Therapeutics

• VASCEPA/VAZKEPA: Amarin Corporation

• Vupanorsen: Pfizer

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @ https://www.delveinsight.com/sample-request/severe-hypertriglyceridemia-shtg-pipeline-insight

Table of Contents

1. Report Introduction

2. Executive Summary

3. Severe Hypertriglyceridemia Current Treatment Patterns

4. Severe Hypertriglyceridemia – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Severe Hypertriglyceridemia Late Stage Products (Phase-III)

7. Severe Hypertriglyceridemia Mid-Stage Products (Phase-II)

8. Severe Hypertriglyceridemia Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Severe Hypertriglyceridemia Discontinued Products

13. Severe Hypertriglyceridemia Product Profiles

14. Key Companies in the Severe Hypertriglyceridemia Market

15. Key Products in the Severe Hypertriglyceridemia Therapeutics Segment

16. Dormant and Discontinued Products

17. Severe Hypertriglyceridemia Unmet Needs

18. Severe Hypertriglyceridemia Future Perspectives

19. Severe Hypertriglyceridemia Analyst Review  

20. Appendix

21. Report Methodology

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Severe Hypertriglyceridemia Pipeline Insights (2024) | Clinical Trials, Latest Approvals, Treatment Options, Key Companies | 89bio, Acasti Pharma, Amarin Corporation, Arrowhead, Ionis Pharmaceuticals

“Vitiligo Pipeline Insights 2024”

DelveInsight’s “Vitiligo – Pipeline Insight, 2024,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in the Vitiligo pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

As per DelveInsight, the Vitiligo therapeutics market is anticipated to grow in the coming years owing to the rise in the number of prevalent cases of Vitiligo, the rise in healthcare spending across the world, and the expected launch of drugs in the market. Some of the key companies in the Vitiligo therapeutics market include ICN Pharmaceuticals, Inc, Valeant Pharmaceuticals, Astellas Pharma, and others.

Vitiligo Overview

Vitiligo is a complex pigment disorder affecting the skin, hair, and occasionally the mucous membranes. It is a long-term condition characterized by the development of pale white patches on the skin, commonly appearing on the face, neck, and hands. Clinically, vitiligo manifests as milk-white, irregularly oval patches of skin that start small but gradually enlarge. The hair growing in the depigmented area also turns white. Vitiligo can be triggered by stress to the melanin-producing cells of the skin, known as melanocytes. Triggers such as sunburn, mechanical trauma, and chemical exposures can initiate an autoimmune response that targets melanocytes, leading to progressive skin depigmentation.

Vitiligo is a multifactorial disorder characterized by the loss of functional melanocytes. Multiple mechanisms have been proposed for melanocyte destruction in vitiligo, including genetic factors, autoimmune responses, oxidative stress, the generation of inflammatory mediators, and melanocyte detachment mechanisms. Both innate and adaptive immunity play roles in the development of vitiligo.

Vitiligo Diagnosis

The diagnosis of vitiligo is primarily clinical, based on the patient’s history, clinical presentation, and family history (including vitiligo and other autoimmune disorders). Key clinical markers of active, progressive disease include Koebner’s phenomenon, trichrome lesions, inflammatory lesions, and confetti-like depigmentation.

Vitiligo Treatment

The optimal treatment of vitiligo depends on the subtype of the disease, the percentage of body surface area (BSA) involved, the impact on the patient’s quality of life, and the patient’s perception of the risk-to-benefit ratio. Treatments aim to stabilize depigmented lesions and stimulate repigmentation and include:

Vitiligo Medications and Topical Treatments:

• Corticosteroids: Can help return color to white patches of skin.

• Calcineurin Inhibitors: Also used to restore skin color.

• Phototherapy:

  • Light Boxes: Used to treat large areas of vitiligo.

  • Laser Treatments: Used for more localized areas.

• Depigmentation Therapy:

  • Removes the color of the natural skin tone to match areas affected by vitiligo.

Vitiligo Surgical Treatments:

• Skin Grafts: Transplant healthy skin to affected areas.

• Cell Transplants: Transfer melanocytes to depigmented areas.

• Successful treatment for vitiligo incorporates three distinct approaches: reducing melanocyte stress, regulating the autoimmune response, and stimulating melanocyte regeneration. It is important to note that treatments may take time, and not everyone responds similarly. Results can vary from one part of the body to another, and new patches may appear during treatment. Often, doctors recommend combining multiple treatments to achieve the best results.

Vitiligo Pipeline Analysis

The report provides insights into: 

• The report provides detailed insights into the emerging therapies for the treatment of Vitiligo and the aggregate therapies developed by major pharma companies.

• It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

• It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

• It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Vitiligo market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Analysis of Emerging Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

• Late stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) 

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

Route of Administration

Vitiligo pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Oral

• Parenteral

• Intravitreal

• Subretinal

• Topical

• Molecule Type

The emerging pipeline products have been categorized under various Molecule types in the report, such as –

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy

Mechanism of Action of the Emerging Pipeline Therapies

• Janus kinase 1 inhibitor

• Emt protein-tyrosine kinase inhibitors

• TYK2 kinase inhibitors

• Syk kinase inhibitors

• Interleukin 15 inhibitors

• HSP70 heat shock protein stimulants

• IFN-γ antagonist

• Melanocortin type 1 receptor modulators

Learn How the Ongoing Clinical & Commercial Activities will Affect the Vitiligo Therapeutic Segment @ https://www.delveinsight.com/sample-request/vitiligo-pipeline-insight

Leading Companies in the Vitiligo Therapeutics Market Include:

• Aclaris Therapeutics

• Amgen

• Arcutis Biotherapeutics

• Arrien Pharmaceuticals

• AXIM Biotechnologies

• Bioniz Therapeutics

• Boston Pharmaceuticals

• Celgene

• Clinuvel Pharmaceuticals

• Dermavant Sciences

• Incyte Corporation

• Pfizer

• Temprian Therapeutics

• TWi Biotechnology

Vitiligo Emerging and Marketed Drugs Profile:

• 1BNZ-1: Bioniz Therapeutics

• AC-1101: TWi Biotechnology

• Afamelanotide: Clinuvel, Inc.

• AMG-714: Amgen

• ATI-1777: Aclaris Therapeutics

• Cerdulatinib: Dermavant Sciences

• PF-06651600: Pfizer

• Phimelanotide – Clinuvel Pharmaceuticals

• Ritlecitinib: Pfizer

• Ruxolitinib: Incyte Corporation

• TT-01: Temprian Therapeutics

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @ https://www.delveinsight.com/sample-request/vitiligo-pipeline-insight

Table of Contents

1. Report Introduction

2. Executive Summary

3. Vitiligo Current Treatment Patterns

4. Vitiligo – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Vitiligo Late Stage Products (Phase-III)

7. Vitiligo Mid-Stage Products (Phase-II)

8. Vitiligo Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Vitiligo Discontinued Products

13. Vitiligo Product Profiles

14. Key Companies in the Vitiligo Market

15. Key Products in the Vitiligo Therapeutics Segment

16. Dormant and Discontinued Products

17. Vitiligo Unmet Needs

18. Vitiligo Future Perspectives

19. Vitiligo Analyst Review  

20. Appendix

21. Report Methodology

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Vitiligo Pipeline Insights (2024) | Clinical Trials, Latest Approvals, Treatment Options, Key Companies | AbbVie, Pfizer, Incyte Corporation, Ahammune Biosciences, Amgen